Diagnostic in immuno-oncology is an innovative field combining the latest discoveries in immunology and new imaging technologies, such as digital pathology.
Our subject at HalioDx is diagnostic in immuno-oncology, a revolutionary therapeutic approach in which therapeutic results are very interesting, but only concern a limited number of patients. To date, it is still unclear how to identify in advance those patients who will respond to new immunotherapeutic antibodies, and even if certain biomarkers are already available, their predictive value is insufficient to decide whether or not to prescribe immunotherapy.
In response, HalioDx develops tests to better characterise the patient’s immune response against cancer, to establish more precisely patient prognosis and to predict their response to treatment, whether they are standard treatments or new immunotherapies.
The Ipsogen adventure, started in 1999 with blood cancers diagnosis, including their rarest forms, allowed me to contribute to the standardisation of technologies for diagnosis and monitoring of leukaemia and, in connection with European networks (EAC; Europe Against Cancer) and ELN (European LeukemiaNet), to establish the medical value of our tests. Today at HalioDx, we apply the same approach. We implement clinical validation plans with diagnostic tests on patient sample collections that are characterised and supplied with clinical data (administered treatments, survival data, etc).
Diagnostic in immuno-oncology is an innovative field combining the latest discoveries in immunology and new imaging technologies, such as digital pathology. In this context, Marseille Immunopôle is an extraordinary lever for developing the entire chain, from prognostic and predictive biomarkers discovery to their clinical validation in routine use to provide patients with personalised care.#industrie
MI should enable us to accelerate discovery, enhance our treatment options and offer more innovative options to our patients through current clinical trials and those of the future.
Unique cluster in the world exclusively dedicated to basic and applied immunology, MI results from an efficient territorial game between research, industry, and the institutional stakeholders in economy and innovation.
CCI Marseille Provence
Marseille Immunopole is born from the will of all partners to do even better and progress faster, and thus allow patients always to keep one step ahead of the disease.
AMU, AP-HM, CIML, INNATE PHARMA
Together, we pursue a simple goal: to better understand the alterations of energetic metabolism in pancreatic cancer cells
AMU, IPC, CRCM